Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1992;1(5):295–308. doi: 10.1155/S0962935192000449

Interactions between rnacrophage cytokines and eicosanoids in expression of antitumour activity

Shlomo Ben-Efraim 1,2
PMCID: PMC2365362  PMID: 18475475

Abstract

Cytokines and eicosanoid products of macrophages play an essential role in expression of antitumour activity of macrophages either in a cell-to-cell contact system between the effector and the target cell or as cell-free soluble products. In this review the relationship between three main monokines, namely TNF-α, IL-1 and IL-6 and the interrelationship between these monokines and eicosanoids (PGE2, PGI2, LTB4, LTC4) in their production and in expression of antitumour activity is discussed. Emphasis is given to the effect of tumour burden on production of the monokines and of the eicosanoids and on the production of these compounds by the tumour cells. Finally, the therapeutic implications drawn from animal studies and clinical trials is discussed.

Full Text

The Full Text of this article is available as a PDF (1.6 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarden L. A., De Groot E. R., Schaap O. L., Lansdorp P. M. Production of hybridoma growth factor by human monocytes. Eur J Immunol. 1987 Oct;17(10):1411–1416. doi: 10.1002/eji.1830171004. [DOI] [PubMed] [Google Scholar]
  2. Adolfs M. J., Fieren M. W., Bonta I. L. Infectious-inflammatory changes in cyclic AMP levels and in their regulation by prostaglandins in human peritoneal macrophages. Prostaglandins Leukot Med. 1985 May;18(2):217–226. doi: 10.1016/0262-1746(85)90021-6. [DOI] [PubMed] [Google Scholar]
  3. Andreesen R., Scheibenbogen C., Brugger W., Krause S., Meerpohl H. G., Leser H. G., Engler H., Löhr G. W. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res. 1990 Dec 1;50(23):7450–7456. [PubMed] [Google Scholar]
  4. Aulitzky W. E., Tilg H., Gastl G., Mull R., Flener R., Vogel W., Herold M., Berger M., Judmaier G., Huber C. Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial. Eur J Cancer. 1991;27(4):462–467. doi: 10.1016/0277-5379(91)90387-s. [DOI] [PubMed] [Google Scholar]
  5. Aznar C., Fitting C., Cavaillon J. M. Lipopolysaccharide-induced production of cytokines by bone marrow-derived macrophages: dissociation between intracellular interleukin 1 production and interleukin 1 release. Cytokine. 1990 Jul;2(4):259–265. doi: 10.1016/1043-4666(90)90026-p. [DOI] [PubMed] [Google Scholar]
  6. Bachwich P. R., Chensue S. W., Larrick J. W., Kunkel S. L. Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages. Biochem Biophys Res Commun. 1986 Apr 14;136(1):94–101. doi: 10.1016/0006-291x(86)90881-8. [DOI] [PubMed] [Google Scholar]
  7. Balkwill F. R., Ward B. G., Moodie E., Fiers W. Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer. Cancer Res. 1987 Sep 15;47(18):4755–4758. [PubMed] [Google Scholar]
  8. Barna B. P., Rogers L. R., Thomassen M. J., Barnett G. H., Estes M. L. Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors. Cancer Immunol Immunother. 1991;33(5):314–318. doi: 10.1007/BF01756596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bartholeyns J., Lopez M., Andreesen R. Adoptive immunotherapy of solid tumors with activated macrophages: experimental and clinical results. Anticancer Res. 1991 May-Jun;11(3):1201–1204. [PubMed] [Google Scholar]
  10. Bauer J., Bauer T. M., Kalb T., Taga T., Lengyel G., Hirano T., Kishimoto T., Acs G., Mayer L., Gerok W. Regulation of interleukin 6 receptor expression in human monocytes and monocyte-derived macrophages. Comparison with the expression in human hepatocytes. J Exp Med. 1989 Nov 1;170(5):1537–1549. doi: 10.1084/jem.170.5.1537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bauer J., Ganter U., Geiger T., Jacobshagen U., Hirano T., Matsuda T., Kishimoto T., Andus T., Acs G., Gerok W. Regulation of interleukin-6 expression in cultured human blood monocytes and monocyte-derived macrophages. Blood. 1988 Oct;72(4):1134–1140. [PubMed] [Google Scholar]
  12. Becker S., Devlin R. B., Haskill J. S. Differential production of tumor necrosis factor, macrophage colony stimulating factor, and interleukin 1 by human alveolar macrophages. J Leukoc Biol. 1989 Apr;45(4):353–361. [PubMed] [Google Scholar]
  13. Ben-Efraim S., Tak C., Bonta I. L. Macrophage cytokines render WEHI-3B tumor cells susceptible to cytostasis by prostaglandins. Prostaglandins Leukot Essent Fatty Acids. 1990 Jun;40(2):163–167. doi: 10.1016/0952-3278(90)90161-d. [DOI] [PubMed] [Google Scholar]
  14. Ben-Efraim S., Tak C., Fieren M. J., Van den Bemd G. J., Bonta I. L. Inflammation amplifies the antitumor cytostasis by human peritoneal macrophages. Med Oncol Tumor Pharmacother. 1991;8(2):87–94. doi: 10.1007/BF02988859. [DOI] [PubMed] [Google Scholar]
  15. Blick M., Sherwin S. A., Rosenblum M., Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987 Jun 1;47(11):2986–2989. [PubMed] [Google Scholar]
  16. Bonta I. L., Elliott G. R., Tak C., Ben-Efraim S. Indomethacin stimulation of macrophage cytostasis against MOPC-315 tumor cells is enhanced by endogenous metabolites of lipoxygenase and counteracted by prostaglandin E2. Agents Actions. 1989 Jan;26(1-2):167–169. doi: 10.1007/BF02126596. [DOI] [PubMed] [Google Scholar]
  17. Brown T. D., Goodman P., Fleming T., Macdonald J. S., Hersh E. M., Braun T. J. A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. J Immunother (1991) 1991 Oct;10(5):376–378. doi: 10.1097/00002371-199110000-00010. [DOI] [PubMed] [Google Scholar]
  18. Brunda M. J., Sulich V., Wright R. B., Palleroni A. V. Tumoricidal activity and cytokine secretion by tumor-infiltrating macrophages. Int J Cancer. 1991 Jul 9;48(5):704–708. doi: 10.1002/ijc.2910480513. [DOI] [PubMed] [Google Scholar]
  19. Callery M. P., Mangino M. J., Kamei T., Flye M. W. Interleukin-6 production by endotoxin-stimulated Kupffer cells is regulated by prostaglandin E2. J Surg Res. 1990 Jun;48(6):523–527. doi: 10.1016/0022-4804(90)90224-p. [DOI] [PubMed] [Google Scholar]
  20. Cameron D. J., Rittenbury M., Majeski J. Ability of cancer patients' macrophages to kill autologous tumor targets. Effect of prostaglandin inhibitors on cytotoxicity. Cancer. 1984 May 15;53(10):2053–2057. doi: 10.1002/1097-0142(19840515)53:10<2053::aid-cncr2820531008>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  21. Cameron D. J., Stromberg B. V. The ability of macrophages from head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors on cytotoxicity. Cancer. 1984 Dec 1;54(11):2403–2408. doi: 10.1002/1097-0142(19841201)54:11<2403::aid-cncr2820541116>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  22. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Chapman P. B., Lester T. J., Casper E. S., Gabrilove J. L., Wong G. Y., Kempin S. J., Gold P. J., Welt S., Warren R. S., Starnes H. F. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987 Dec;5(12):1942–1951. doi: 10.1200/JCO.1987.5.12.1942. [DOI] [PubMed] [Google Scholar]
  24. Chen L., Mory Y., Zilberstein A., Revel M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2. Proc Natl Acad Sci U S A. 1988 Nov;85(21):8037–8041. doi: 10.1073/pnas.85.21.8037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Chensue S. W., Shmyr-Forsch C., Weng A., Otterness I. G., Kunkel S. L. Biologic and immunohistochemical analysis of macrophage interleukin- 1 alpha, - 1 beta, and tumor necrosis factor production during the peritoneal exudative response. J Leukoc Biol. 1989 Dec;46(6):529–537. doi: 10.1002/jlb.46.6.529. [DOI] [PubMed] [Google Scholar]
  26. Chokri M., Freudenberg M., Galanos C., Poindron P., Bartholeyns J. Antitumoral effects of lipopolysaccharides, tumor necrosis factor, interferon and activated macrophages: synergism and tissue distribution. Anticancer Res. 1989 Jul-Aug;9(4):1185–1190. [PubMed] [Google Scholar]
  27. Cozzolino F., Rubartelli A., Aldinucci D., Sitia R., Torcia M., Shaw A., Di Guglielmo R. Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2369–2373. doi: 10.1073/pnas.86.7.2369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Creaven P. J., Plager J. E., Dupere S., Huben R. P., Takita H., Mittelman A., Proefrock A. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol. 1987;20(2):137–144. doi: 10.1007/BF00253968. [DOI] [PubMed] [Google Scholar]
  29. Denis M., Ghadirian E. Human monocyte tumouristatic ability: modulation by cytokines and tumour cell products. Int J Immunopharmacol. 1990;12(5):509–513. doi: 10.1016/0192-0561(90)90114-3. [DOI] [PubMed] [Google Scholar]
  30. Dinarello C. A., Bishai I., Rosenwasser L. J., Coceani F. The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activating factor (interleukin-1). Int J Immunopharmacol. 1984;6(1):43–50. doi: 10.1016/0192-0561(84)90033-x. [DOI] [PubMed] [Google Scholar]
  31. Dinarello C. A., Cannon J. G., Wolff S. M., Bernheim H. A., Beutler B., Cerami A., Figari I. S., Palladino M. A., Jr, O'Connor J. V. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1433–1450. doi: 10.1084/jem.163.6.1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Dinarello C. A. The biology of interleukin 1 and comparison to tumor necrosis factor. Immunol Lett. 1987 Dec;16(3-4):227–231. doi: 10.1016/0165-2478(87)90151-9. [DOI] [PubMed] [Google Scholar]
  33. Donaldson J. T., Keane T. E., Poulton S. H., Walther P. J. Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model. Urol Res. 1990;18(4):245–250. doi: 10.1007/BF00294766. [DOI] [PubMed] [Google Scholar]
  34. Drapier J. C., Petit J. F. Development of antitumor activity in LPS-stimulated mouse granuloma macrophages. Regulation by eicosanoids. Inflammation. 1986 Jun;10(2):195–204. doi: 10.1007/BF00916001. [DOI] [PubMed] [Google Scholar]
  35. Economou J. S., Colquhoun S. D., Anderson T. M., McBride W. W., Golub S., Holmes E. C., Morton D. L. Interleukin-1 and tumor necrosis factor production by tumor-associated mononuclear leukocytes and peripheral mononuclear leukocytes in cancer patients. Int J Cancer. 1988 Nov 15;42(5):712–714. doi: 10.1002/ijc.2910420514. [DOI] [PubMed] [Google Scholar]
  36. Elliott G. R., Tak C., Pellens C., Ben-Efraim S., Bonta I. L. Indomethacin stimulation of macrophage cytostasis against MOPC-315 tumor cells is inhibited by both prostaglandin E2 and nordihydroguaiaretic acid, a lipoxygenase inhibitor. Cancer Immunol Immunother. 1988;27(2):133–136. doi: 10.1007/BF00200017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Erroi A., Sironi M., Chiaffarino F., Chen Z. G., Mengozzi M., Mantovani A. IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma. Int J Cancer. 1989 Nov 15;44(5):795–801. doi: 10.1002/ijc.2910440508. [DOI] [PubMed] [Google Scholar]
  38. Farrar W. L., Humes J. L. The role of arachidonic acid metabolism in the activities of interleukin 1 and 2. J Immunol. 1985 Aug;135(2):1153–1159. [PubMed] [Google Scholar]
  39. Fieren M. W., Van den Bemd G. J., Bonta I. L. Endotoxin-stimulated peritoneal macrophages obtained from continuous ambulatory peritoneal dialysis patients show an increased capacity to release interleukin-1 beta in vitro during infectious peritonitis. Eur J Clin Invest. 1990 Aug;20(4):453–457. doi: 10.1111/j.1365-2362.1990.tb01883.x. [DOI] [PubMed] [Google Scholar]
  40. Fieren M. W., van den Bemd G. J., Ben-Efraim S., Bonta I. L. Prostaglandin E2 inhibits the release of tumor necrosis factor-alpha, rather than interleukin 1 beta, from human macrophages. Immunol Lett. 1992 Jan;31(1):85–90. doi: 10.1016/0165-2478(92)90015-g. [DOI] [PubMed] [Google Scholar]
  41. Fraker D. L., Langstein H. N., Norton J. A. Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J Exp Med. 1989 Sep 1;170(3):1015–1020. doi: 10.1084/jem.170.3.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Fraker D. L., Sheppard B. C., Norton J. A. Impact of tolerance on antitumor efficacy of tumor necrosis factor in mice. Cancer Res. 1990 Apr 15;50(8):2261–2267. [PubMed] [Google Scholar]
  43. Furuta Y., Hall E. R., Sanduja S., Barkley T., Jr, Milas L. Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res. 1988 Jun 1;48(11):3002–3007. [PubMed] [Google Scholar]
  44. Gagnon L., Filion L. G., Dubois C., Rola-Pleszczynski M. Leukotrienes and macrophage activation: augmented cytotoxic activity and enhanced interleukin 1, tumor necrosis factor and hydrogen peroxide production. Agents Actions. 1989 Jan;26(1-2):141–147. doi: 10.1007/BF02126587. [DOI] [PubMed] [Google Scholar]
  45. Gatanaga T., Hwang C. D., Kohr W., Cappuccini F., Lucci J. A., 3rd, Jeffes E. W., Lentz R., Tomich J., Yamamoto R. S., Granger G. A. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8781–8784. doi: 10.1073/pnas.87.22.8781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Gelin J., Moldawer L. L., Lonnroth C., deMan P., Svanborg-Eden C., Lowry S. F., Lundholm K. G. Appearance of hybridoma growth factor/interleukin-6 in the serum of mice bearing a methylcholanthrene-induced sarcoma. Biochem Biophys Res Commun. 1988 Dec 15;157(2):575–579. doi: 10.1016/s0006-291x(88)80288-2. [DOI] [PubMed] [Google Scholar]
  47. Gery I., Gershon R. K., Waksman B. H. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J Exp Med. 1972 Jul 1;136(1):128–142. doi: 10.1084/jem.136.1.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Gery I., Waksman B. H. Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med. 1972 Jul 1;136(1):143–155. doi: 10.1084/jem.136.1.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Goetzl E. J., Hill H. R., Gorman R. R. Unique aspects of the modulation of human neutrophil function by 12-L-hydroperoxy-5,8,10,14-eicosatetraenoic acid. Prostaglandins. 1980 Jan;19(1):71–85. doi: 10.1016/0090-6980(80)90155-0. [DOI] [PubMed] [Google Scholar]
  50. Haranaka K., Satomi N., Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer. 1984 Aug 15;34(2):263–267. doi: 10.1002/ijc.2910340219. [DOI] [PubMed] [Google Scholar]
  51. Helle M., Brakenhoff J. P., De Groot E. R., Aarden L. A. Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol. 1988 Jun;18(6):957–959. doi: 10.1002/eji.1830180619. [DOI] [PubMed] [Google Scholar]
  52. Hersh E. M., Metch B. S., Muggia F. M., Brown T. D., Whitehead R. P., Budd G. T., Rinehart J. J., Crawford E. D., Bonnet J. D., Behrens B. C. Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J Immunother (1991) 1991 Dec;10(6):426–431. doi: 10.1097/00002371-199112000-00006. [DOI] [PubMed] [Google Scholar]
  53. Hidaka T., Tsuruta M., Tomita Y., Inokuchi T., Sugiyama M., Ogura R. Generation of leukotrienes and hydroxyeicosatetraenoic acids in peritoneal macrophages of tumor-bearing mice. Prostaglandins Leukot Essent Fatty Acids. 1991 Nov;44(3):185–190. doi: 10.1016/0952-3278(91)90054-9. [DOI] [PubMed] [Google Scholar]
  54. Honn K. V., Bockman R. S., Marnett L. J. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins. 1981 May;21(5):833–864. doi: 10.1016/0090-6980(81)90240-9. [DOI] [PubMed] [Google Scholar]
  55. Hubbard W. C., Alley M. C., McLemore T. L., Boyd M. R. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors. Cancer Res. 1988 Sep 1;48(17):4770–4775. [PubMed] [Google Scholar]
  56. Ikeda M., Sakagami H., Nishida H., Hatta Y., Fukushima Y. Inhibition of tumor necrosis factor-stimulated human peripheral blood polymorphonuclear cell iodination by sera from various cancer patients. Anticancer Res. 1991 Sep-Oct;11(5):1745–1749. [PubMed] [Google Scholar]
  57. Ikemoto S., Kishimoto T., Nishio S., Wada S., Maekawa M. Correlation of tumor necrosis factor and prostaglandin E2 production of monocytes in bladder cancer patients. Cancer. 1989 Nov 15;64(10):2076–2080. doi: 10.1002/1097-0142(19891115)64:10<2076::aid-cncr2820641018>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  58. Jablons D. M., McIntosh J. K., Mulé J. J., Nordan R. P., Rudikoff S., Lotze M. T. Induction of interferon-beta 2/interleukin-6 (IL-6) by cytokine administration and detection of circulating interleukin-6 in the tumor-bearing state. Ann N Y Acad Sci. 1989;557:157–161. doi: 10.1111/j.1749-6632.1989.tb24008.x. [DOI] [PubMed] [Google Scholar]
  59. Jänicke R., Männel D. N. Distinct tumor cell membrane constituents activate human monocytes for tumor necrosis factor synthesis. J Immunol. 1990 Feb 1;144(3):1144–1150. [PubMed] [Google Scholar]
  60. Karck U., Peters T., Decker K. The release of tumor necrosis factor from endotoxin-stimulated rat Kupffer cells is regulated by prostaglandin E2 and dexamethasone. J Hepatol. 1988 Dec;7(3):352–361. doi: 10.1016/s0168-8278(88)80008-4. [DOI] [PubMed] [Google Scholar]
  61. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988 Mar 3;332(6159):83–85. doi: 10.1038/332083a0. [DOI] [PubMed] [Google Scholar]
  62. Kist A., Ho A. D., Räth U., Wiedenmann B., Bauer A., Schlick E., Kirchner H., Männel D. N. Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor. Blood. 1988 Jul;72(1):344–348. [PubMed] [Google Scholar]
  63. Knudsen P. J., Dinarello C. A., Strom T. B. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol. 1986 Nov 15;137(10):3189–3194. [PubMed] [Google Scholar]
  64. Kobari L., Weil D., Lemoine F. M., Dubois C., Thiam D., Baillou C., Guigon M., Gorin N. C., Najman A. Secretion of tumor necrosis factor-alpha by fresh human acute nonlymphoblastic leukemic cells: role in the disappearance of normal CFU-GM progenitors. Exp Hematol. 1990 Dec;18(11):1187–1192. [PubMed] [Google Scholar]
  65. Kolitz J. E., Mertelsmann R. The immunotherapy of human cancer with interleukin 2: present status and future directions. Cancer Invest. 1991;9(5):529–542. doi: 10.3109/07357909109018951. [DOI] [PubMed] [Google Scholar]
  66. Komatsu H., Yaju H., Chiba K., Okumoto T. Inhibition by cyclo-oxygenase inhibitors of interleukin-6 production by human peripheral blood mononuclear cells. Int J Immunopharmacol. 1991;13(8):1137–1146. doi: 10.1016/0192-0561(91)90165-4. [DOI] [PubMed] [Google Scholar]
  67. Kort W. J., Zijlstra F. J., Weijma I. M. Eicosanoid synthesis by alveolar macrophages in rats with malignant mammary tumors: differences in rats treated with and without carrageenan implants. Prostaglandins Leukot Essent Fatty Acids. 1989 Aug;37(2):113–120. doi: 10.1016/0952-3278(89)90107-5. [DOI] [PubMed] [Google Scholar]
  68. Kotloff R. M., Little J., Elias J. A. Human alveolar macrophage and blood monocyte interleukin-6 production. Am J Respir Cell Mol Biol. 1990 Nov;3(5):497–505. doi: 10.1165/ajrcmb/3.5.497. [DOI] [PubMed] [Google Scholar]
  69. Kovacs E. J., Radzioch D., Young H. A., Varesio L. Differential inhibition of IL-1 and TNF-alpha mRNA expression by agents which block second messenger pathways in murine macrophages. J Immunol. 1988 Nov 1;141(9):3101–3105. [PubMed] [Google Scholar]
  70. Krosnick J. A., McIntosh J. K., Mulé J. J., Rosenberg S. A. Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor alpha in normal and tumor-bearing mice. Cancer Immunol Immunother. 1989;30(3):133–138. doi: 10.1007/BF01669420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Kunkel S. L., Chensue S. W., Phan S. H. Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol. 1986 Jan;136(1):186–192. [PubMed] [Google Scholar]
  72. Kunkel S. L., Spengler M., May M. A., Spengler R., Larrick J., Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem. 1988 Apr 15;263(11):5380–5384. [PubMed] [Google Scholar]
  73. Lala P. K., Parhar R. S. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ. Cancer Res. 1988 Mar 1;48(5):1072–1079. [PubMed] [Google Scholar]
  74. Lala P. K., Parhar R. S., Singh P. Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cell Immunol. 1986 Apr 15;99(1):108–118. doi: 10.1016/0008-8749(86)90220-0. [DOI] [PubMed] [Google Scholar]
  75. Lala P. K., Parhar R. S., Singh P., Lala P. K. Cure of murine Ehrlich ascites tumors with chronic oral indomethacin therapy combined with intraperitoneal administration of LAK cells and IL-2. Cancer Lett. 1990 May 15;51(1):27–35. doi: 10.1016/0304-3835(90)90227-o. [DOI] [PubMed] [Google Scholar]
  76. Lepoivre M., Boudbid H., Lemaire G., Petit J. F. Cytostatic product(s) released by activated macrophages, unrelated to interleukin 1, tumor necrosis factor alpha, and interferon-alpha/beta. Cell Immunol. 1988 Sep;115(2):273–287. doi: 10.1016/0008-8749(88)90181-5. [DOI] [PubMed] [Google Scholar]
  77. Lönnroth C., Moldawer L. L., Gelin J., Kindblom L., Sherry B., Lundholm K. Tumor necrosis factor-alpha and interleukin-1 alpha production in cachectic, tumor-bearing mice. Int J Cancer. 1990 Nov 15;46(5):889–896. doi: 10.1002/ijc.2910460523. [DOI] [PubMed] [Google Scholar]
  78. Maca R. D. Inhibition of the growth of Lewis lung carcinoma by indomethacin in conventional, nude, and beige mice. J Biol Response Mod. 1988 Dec;7(6):568–580. [PubMed] [Google Scholar]
  79. Mahan M., Meunier J., Newby M., Young M. R. Prostaglandin E2 production by EL 4 leukemia cells from C57BL/6 mice: mechanism for tumor dissemination. J Natl Cancer Inst. 1985 Jan;74(1):191–195. [PubMed] [Google Scholar]
  80. Malick A. P., Elgert K. D., Garner R. E., Adkinson N. F., Jr Prostaglandin E2 production by Mac-2+ macrophages: tumor-induced population shift. J Leukoc Biol. 1987 Dec;42(6):673–681. doi: 10.1002/jlb.42.6.673. [DOI] [PubMed] [Google Scholar]
  81. Mantovani A., Ming W. J., Balotta C., Abdeljalil B., Bottazzi B. Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor. Biochim Biophys Acta. 1986 Aug 5;865(1):59–67. doi: 10.1016/0304-419x(86)90013-2. [DOI] [PubMed] [Google Scholar]
  82. Marquet R. L., de Bruin R. W., Eggermont A. M., Jeekel J. Treatment of colon cancer in rats with rMuTNF and the interferon-inducer bropirimine. Agents Actions. 1989 Jan;26(1-2):151–152. doi: 10.1007/BF02126589. [DOI] [PubMed] [Google Scholar]
  83. McBride W. H. Phenotype and functions of intratumoral macrophages. Biochim Biophys Acta. 1986 Aug 5;865(1):27–41. doi: 10.1016/0304-419x(86)90011-9. [DOI] [PubMed] [Google Scholar]
  84. Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., Sonoda T., Hirano T., Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989 Jul 3;250(2):607–610. doi: 10.1016/0014-5793(89)80805-1. [DOI] [PubMed] [Google Scholar]
  85. Moldawer L. L., Lonnroth C., Mizel S. B., Lundholm K. G. Down-regulation of interleukin 1 production by macrophages of sarcoma-bearing mice. J Immunol. 1987 Jun 15;138(12):4270–4274. [PubMed] [Google Scholar]
  86. Morikawa K., Fidler I. J. Heterogeneous response of human colon cancer cells to the cytostatic and cytotoxic effects of recombinant human cytokines: interferon-alpha, interferon-gamma, tumor necrosis factor, and interleukin-1. J Biol Response Mod. 1989 Apr;8(2):206–218. [PubMed] [Google Scholar]
  87. Mulé J. J., McIntosh J. K., Jablons D. M., Rosenberg S. A. Antitumor activity of recombinant interleukin 6 in mice. J Exp Med. 1990 Mar 1;171(3):629–636. doi: 10.1084/jem.171.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Männel D. N., Jänicke R., Westenfelder U., Echtenacher B., Kist A., Falk W. Tumor-induced tumor necrosis factor production in macrophages. Lymphokine Res. 1990 Winter;9(4):485–489. [PubMed] [Google Scholar]
  89. Nakazawa I., Ohuchi K., Watanabe M., Tsurufuji S. A difference in prostaglandin E2 synthesis between cancer cells metastasizing into liver and kidney. Prostaglandins Leukot Med. 1985 Feb;17(2):265–266. doi: 10.1016/0262-1746(85)90113-1. [DOI] [PubMed] [Google Scholar]
  90. Naomoto Y., Tanaka N., Orita K. Antitumor effect of natural human tumor necrosis factor-alpha and natural human interferon-alpha in combination against human cancer transplanted into nude mice. Acta Med Okayama. 1989 Aug;43(4):211–221. doi: 10.18926/AMO/30855. [DOI] [PubMed] [Google Scholar]
  91. Nara K., Odagiri H., Fujii M., Yamanaka Y., Yokoyama M., Morita T., Sasaki M., Kon M., Abo T. Increased production of tumor necrosis factor and prostaglandin E2 by monocytes in cancer patients and its unique modulation by their plasma. Cancer Immunol Immunother. 1987;25(2):126–132. doi: 10.1007/BF00199952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Nawroth P. P., Bank I., Handley D., Cassimeris J., Chess L., Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1363–1375. doi: 10.1084/jem.163.6.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Negrier M. S., Pourreau C. N., Palmer P. A., Ranchere J. Y., Mercatello A., Viens P., Blaise D., Jasmin C., Misset J. L., Franks C. R. Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer. J Immunother (1991) 1992 Feb;11(2):93–102. doi: 10.1097/00002371-199202000-00003. [DOI] [PubMed] [Google Scholar]
  94. Noguchi K., Inagawa H., Tsuji Y., Morikawa A., Mizuno D., Soma G. Antitumor activity of a novel chimera tumor necrosis factor (TNF-STH) constructed by connecting rTNF-S with thymosin beta 4 against murine syngeneic tumors. J Immunother (1991) 1991 Apr;10(2):105–111. doi: 10.1097/00002371-199104000-00004. [DOI] [PubMed] [Google Scholar]
  95. Numata A., Minagawa T., Asano M., Nakane A., Katoh H., Tanabe T. Functional evaluation of tumor-infiltrating mononuclear cells. Detection of endogenous interferon-gamma and tumor necrosis factor-alpha in human colorectal adenocarcinomas. Cancer. 1991 Nov 1;68(9):1937–1943. doi: 10.1002/1097-0142(19911101)68:9<1937::aid-cncr2820680916>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  96. Ohno I., Tanno Y., Yamauchi K., Takishima T. Production of tumour necrosis factor by mastocytoma P815 cells. Immunology. 1990 Feb;69(2):312–315. [PMC free article] [PubMed] [Google Scholar]
  97. Onozaki K., Matsushima K., Aggarwal B. B., Oppenheim J. J. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol. 1985 Dec;135(6):3962–3968. [PubMed] [Google Scholar]
  98. Ophir R., Ben-Efraim S., Bonta I. L. Leukotriene D4 and indomethacin enhance additively the macrophage cytostatic activity in vitro towards MOPC-315 tumour cells. Int J Tissue React. 1987;9(3):189–194. [PubMed] [Google Scholar]
  99. Palladino M. A., Jr, Shalaby M. R., Kramer S. M., Ferraiolo B. L., Baughman R. A., Deleo A. B., Crase D., Marafino B., Aggarwal B. B., Figari I. S. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol. 1987 Jun 1;138(11):4023–4032. [PubMed] [Google Scholar]
  100. Parhar R. S., Lala P. K. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. J Leukoc Biol. 1988 Dec;44(6):474–484. doi: 10.1002/jlb.44.6.474. [DOI] [PubMed] [Google Scholar]
  101. Peri G., Rossi V., Taraboletti G., Erroi A., Mantovani A. Ia antigen expression and IL-1 activity in murine tumour-associated macrophages. Immunology. 1986 Dec;59(4):527–533. [PMC free article] [PubMed] [Google Scholar]
  102. Plescia O. J., Pontieri G. M., Brown J., Racis S., Ippoliti F., Bellelli L., Sezzi M. L., Lipari M. Amplification by macrophages of prostaglandin-mediated immunosuppression in mice bearing syngeneic tumors. Prostaglandins Leukot Med. 1984 Nov;16(2):205–223. doi: 10.1016/0262-1746(84)90072-6. [DOI] [PubMed] [Google Scholar]
  103. Poubelle P. E., Stankova J., Grassi J., Rola-Pleszczynski M. Leukotriene B4 up-regulates IL-6 rather than IL-1 synthesis in human monocytes. Agents Actions. 1991 Sep;34(1-2):42–45. doi: 10.1007/BF01993233. [DOI] [PubMed] [Google Scholar]
  104. Poupart P., Vandenabeele P., Cayphas S., Van Snick J., Haegeman G., Kruys V., Fiers W., Content J. B cell growth modulating and differentiating activity of recombinant human 26-kd protein (BSF-2, HuIFN-beta 2, HPGF). EMBO J. 1987 May;6(5):1219–1224. doi: 10.1002/j.1460-2075.1987.tb02357.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Raddassi K., Tenu J. P., Pradelles P., Lemaire G. Arachidonate metabolism triggered in primed macrophages by signals inducing antitumor activity. J Lipid Mediat. 1991 Sep-Oct;4(2):185–198. [PubMed] [Google Scholar]
  106. Riesenfeld-Orn I., Wolpe S., Garcia-Bustos J. F., Hoffmann M. K., Tuomanen E. Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components. Infect Immun. 1989 Jul;57(7):1890–1893. doi: 10.1128/iai.57.7.1890-1893.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Rola-Pleszczynski M., Lemaire I. Leukotrienes augment interleukin 1 production by human monocytes. J Immunol. 1985 Dec;135(6):3958–3961. [PubMed] [Google Scholar]
  108. Rolland P. H., Martin P. M., Jacquemier J., Rolland A. M., Toga M. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst. 1980 May;64(5):1061–1070. [PubMed] [Google Scholar]
  109. Rosztoczy I., Content J. The effects of various cytokines on interleukin-6 and interferon-alpha synthesis in human peripheral blood mononuclear cells. J Interferon Res. 1990 Dec;10(6):637–645. doi: 10.1089/jir.1990.10.637. [DOI] [PubMed] [Google Scholar]
  110. Räth U., Kaufmann M., Schmid H., Hofmann J., Wiedenmann B., Kist A., Kempeni J., Schlick E., Bastert G., Kommerell B. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer. 1991;27(2):121–125. doi: 10.1016/0277-5379(91)90467-r. [DOI] [PubMed] [Google Scholar]
  111. Santoro M. G., Benedetto A., Jaffe B. M. Prostaglandin A1 induces differentiation in Friend erythroleukemia cells. Prostaglandins. 1979 May;17(5):719–727. doi: 10.1016/s0090-6980(79)80043-x. [DOI] [PubMed] [Google Scholar]
  112. Santoro M. G., Philpott G. W., Jaffe B. M. Inhibition of tumour growth in vivo and in vitro by prostaglandin E. Nature. 1976 Oct 28;263(5580):777–779. doi: 10.1038/263777a0. [DOI] [PubMed] [Google Scholar]
  113. Scales W. E., Chensue S. W., Otterness I., Kunkel S. L. Regulation of monokine gene expression: prostaglandin E2 suppresses tumor necrosis factor but not interleukin-1 alpha or beta-mRNA and cell-associated bioactivity. J Leukoc Biol. 1989 May;45(5):416–421. [PubMed] [Google Scholar]
  114. Schade U. F., Engel R., Jakobs D. The role of lipoxygenases in endotoxin-induced cytokine production. Prog Clin Biol Res. 1991;367:73–82. [PubMed] [Google Scholar]
  115. Schade U. F., Ernst M., Reinke M., Wolter D. T. Lipoxygenase inhibitors suppress formation of tumor necrosis factor in vitro and in vivo. Biochem Biophys Res Commun. 1989 Mar 15;159(2):748–754. doi: 10.1016/0006-291x(89)90058-2. [DOI] [PubMed] [Google Scholar]
  116. Scheringa M., Keizer A., Jeekel J., Marquet R. L. Anti-tumor effect of recombinant murine TNF-alpha (rMuTNFa) given by continuous i.v. infusion as compared to repeated i.v. injections in a rat liver metastasis model. Int J Cancer. 1989 May 15;43(5):905–909. doi: 10.1002/ijc.2910430529. [DOI] [PubMed] [Google Scholar]
  117. Schiller J. H., Storer B. E., Witt P. L., Alberti D., Tombes M. B., Arzoomanian R., Proctor R. A., McCarthy D., Brown R. R., Voss S. D. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res. 1991 Mar 15;51(6):1651–1658. [PubMed] [Google Scholar]
  118. Schindler R., Mancilla J., Endres S., Ghorbani R., Clark S. C., Dinarello C. A. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990 Jan 1;75(1):40–47. [PubMed] [Google Scholar]
  119. Selby P., Hobbs S., Viner C., Jackson E., Jones A., Newell D., Calvert A. H., McElwain T., Fearon K., Humphreys J. Tumour necrosis factor in man: clinical and biological observations. Br J Cancer. 1987 Dec;56(6):803–808. doi: 10.1038/bjc.1987.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Semenzato G. Tumour necrosis factor: a cytokine with multiple biological activities. Br J Cancer. 1990 Mar;61(3):354–361. doi: 10.1038/bjc.1990.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Shepard H. M., Lewis G. D. Resistance of tumor cells to tumor necrosis factor. J Clin Immunol. 1988 Sep;8(5):333–341. doi: 10.1007/BF00917148. [DOI] [PubMed] [Google Scholar]
  122. Sher T., Rottem S., Gallily R. Mycoplasma capricolum membranes induce tumor necrosis factor alpha by a mechanism different from that of lipopolysaccharide. Cancer Immunol Immunother. 1990;31(2):86–92. doi: 10.1007/BF01742371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Siegall C. B., Schwab G., Nordan R. P., FitzGerald D. J., Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res. 1990 Dec 15;50(24):7786–7788. [PubMed] [Google Scholar]
  124. Siziopikou K. P., Harris J. E., Casey L., Nawas Y., Braun D. P. Impaired tumoricidal function of alveolar macrophages from patients with non-small cell lung cancer. Cancer. 1991 Sep 1;68(5):1035–1044. doi: 10.1002/1097-0142(19910901)68:5<1035::aid-cncr2820680522>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  125. Skillings J., Wierzbicki R., Eisenhauer E., Venner P., Letendre F., Stewart D., Weinerman B. A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Immunother (1991) 1992 Jan;11(1):67–70. doi: 10.1097/00002371-199201000-00008. [DOI] [PubMed] [Google Scholar]
  126. Smith D. M., Lackides G. A., Epstein L. B. Coordinated induction of autocrine tumor necrosis factor and interleukin 1 in normal human monocytes and the implications for monocyte-mediated cytotoxicity. Cancer Res. 1990 Jun 1;50(11):3146–3153. [PubMed] [Google Scholar]
  127. Smith J. W., 2nd, Urba W. J., Clark J. W., Longo D. L., Farrell M., Creekmore S. P., Conlon K. C., Jaffe H., Steis R. G. Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma. J Immunother (1991) 1991 Oct;10(5):355–362. doi: 10.1097/00002371-199110000-00007. [DOI] [PubMed] [Google Scholar]
  128. Snider M. E., Fertel R. H., Zwilling B. S. Prostaglandin regulation of macrophage function: effect of endogenous and exogenous prostaglandins. Cell Immunol. 1982 Dec;74(2):234–242. doi: 10.1016/0008-8749(82)90024-7. [DOI] [PubMed] [Google Scholar]
  129. Spengler R. N., Spengler M. L., Lincoln P., Remick D. G., Strieter R. M., Kunkel S. L. Dynamics of dibutyryl cyclic AMP- and prostaglandin E2-mediated suppression of lipopolysaccharide-induced tumor necrosis factor alpha gene expression. Infect Immun. 1989 Sep;57(9):2837–2841. doi: 10.1128/iai.57.9.2837-2841.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Sugarman B. J., Aggarwal B. B., Hass P. E., Figari I. S., Palladino M. A., Jr, Shepard H. M. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985 Nov 22;230(4728):943–945. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  131. Sykes J. A., Moddox I. S. Prostaglandin production by experimental tumours and effects of anti-inflammatory compounds. Nat New Biol. 1972 May 10;237(71):59–61. doi: 10.1038/newbio237059a0. [DOI] [PubMed] [Google Scholar]
  132. Sébahoun G., Maraninchi D., Carcassonne Y. Increased prostaglandin E production in malignant lymphomas. Acta Haematol. 1985;74(3):132–136. doi: 10.1159/000206188. [DOI] [PubMed] [Google Scholar]
  133. Taffet S. M., Eurell T. E., Russell S. W. Regulation of macrophage-mediated tumor cell killing by prostaglandins: comparison of the effects of PGE2 and PGI2. Prostaglandins. 1982 Dec;24(6):763–774. doi: 10.1016/0090-6980(82)90057-0. [DOI] [PubMed] [Google Scholar]
  134. Utsugi T., Fidler I. J. Prostaglandin E2 does not inhibit tumoricidal activity of mouse macrophages against adherent tumor cells. J Immunol. 1991 Mar 15;146(6):2066–2071. [PubMed] [Google Scholar]
  135. Van Hilten J. A., Elliott G. R., Bonta I. L. Specific lipoxygenase inhibition reverses macrophage cytotasis towards P815 tumor cells in vitro induced by the calcium ionophore A23187. Prostaglandins Leukot Essent Fatty Acids. 1988 Dec;34(3):187–192. doi: 10.1016/0952-3278(88)90144-5. [DOI] [PubMed] [Google Scholar]
  136. Van Moorselaar R. J., Schwachöfer J. H., Crooijmans R. P., Van Stratum P., Debruyne F. M., Schalken J. A. Combined effects of tumor necrosis factor alpha and radiation in the treatment of renal cell carcinoma grown as radia spheroids. Anticancer Res. 1990 Nov-Dec;10(6):1769–1773. [PubMed] [Google Scholar]
  137. Vincent J. E., Vermeer M. A., Kort W. J., Zijlstra F. J. The formation of thromboxane B2, leukotriene B4 and 12-hydroxyeicosatetraenoic acid by alveolar macrophages after activation during tumor growth in the rat. Biochim Biophys Acta. 1990 Feb 6;1042(2):255–258. doi: 10.1016/0005-2760(90)90017-r. [DOI] [PubMed] [Google Scholar]
  138. Weissenbach J., Chernajovsky Y., Zeevi M., Shulman L., Soreq H., Nir U., Wallach D., Perricaudet M., Tiollais P., Revel M. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7152–7156. doi: 10.1073/pnas.77.12.7152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Whitehead R. P., Fleming T., Macdonald J. S., Goodman P. J., Neefe J., Braun T. J., Swinnen L. J., Hersh E. M. A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study. J Biol Response Mod. 1990 Dec;9(6):588–591. [PubMed] [Google Scholar]
  140. Wilson K. M., Lord E. M. Specific (EMT6) and non-specific (WEHI-164) cytolytic activity by host cells infiltrating tumour spheroids. Br J Cancer. 1987 Feb;55(2):141–146. doi: 10.1038/bjc.1987.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Wilson K. M., Siegal G., Lord E. M. Tumor necrosis factor-mediated cytotoxicity by tumor-associated macrophages. Cell Immunol. 1989 Oct 1;123(1):158–165. doi: 10.1016/0008-8749(89)90276-1. [DOI] [PubMed] [Google Scholar]
  142. Young M. R., Hoover C. S. Inhibition of spleen cell cytotoxic capacity toward tumor by elevated prostaglandin E2 levels in mice bearing Lewis lung carcinoma. J Natl Cancer Inst. 1986 Aug;77(2):425–429. [PubMed] [Google Scholar]
  143. Zielinski C. C., Mueller C., Tyl E., Tichatschek E., Kubista E., Spona J. Impaired production of tumor necrosis factor in breast cancer. Cancer. 1990 Nov 1;66(9):1944–1948. doi: 10.1002/1097-0142(19901101)66:9<1944::aid-cncr2820660916>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  144. van Hilten J. A., Ben Efraim S., Zijlstra F. J., Bonta I. L. Leukotriene C4 is an essential 5-lipoxygenase intermediate in A23187-induced macrophage cytostatic activity against P815 tumor cells. Prostaglandins Leukot Essent Fatty Acids. 1990 Apr;39(4):283–290. doi: 10.1016/0952-3278(90)90007-8. [DOI] [PubMed] [Google Scholar]
  145. van der Schoot C. E., Jansen P., Poorter M., Wester M. R., von dem Borne A. E., Aarden L. A., van Oers R. H. Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation. Blood. 1989 Nov 1;74(6):2081–2087. [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES